A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Biliary Tract Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically confirmed adenocarcinoma of the biliary tract (intrahepatic or extrahepatic CCA or muscle invasive GBC) who have undergone macroscopically complete resection with curative intent (R0 or R1)
    2. Participants with mixed-type histology are eligible if adenocarcinoma or adenosquamous carcinoma is predominant
    3. Confirmed disease-free status by imaging (CT or MRI) and no moderate-to-severe ascites within 28 days prior to randomization

You may not be eligible for this study if the following are true:

    1. Participants with locally-advanced, unresectable, or metastatic disease at initial diagnosis
    2. Ampullary cancer, neuroendocrine, mixed neuroendocrine and non-neuroendocrine neoplasms and nonepithelial tumors
    3. Thromboembolic event within 3 months before the first dose of investigational product



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.